Ionis Pharmaceuticals (IONS) -
Event summary combining transcript, slides, and related documents.
Latest events from Ionis Pharmaceuticals
- FDA approved ZANVASTRO as the first disease-modifying therapy for Alexander disease.IONS
FDA announcement - Strong revenue growth and product launches in H1 2026 support a positive full-year outlook.IONSQ2 2026
- Priority review for olezarsen and robust late-stage pipeline drive strong growth outlook.IONSOppenheimer 36th Annual Healthcare Life Sciences Conference
- Poised for multi-billion dollar revenue growth with multiple late-stage launches and strong clinical momentum.IONSStatus Update
- 2025 revenue rose 34% to $944M, with strong launches and ~20% growth expected in 2026.IONSQ4 2025
- Strong product launches, robust pipeline, and innovative therapies set up for major growth next year.IONSJefferies London Healthcare Conference 2025
- Accelerating launches and innovation drive a clear path to $5B+ peak revenues and cash flow break-even by 2028.IONSInnovation Day 2025
- Q2 2025 revenue doubled to $452M, prompting a guidance increase and strong growth outlook.IONSQ2 2025
- Q1 2025 revenue up 10% to $132M; 2025 guidance raised over 20% on strong launches and royalties.IONSQ1 2025
- TRYNGOLZA and WAINUA launches fueled revenue growth and a strong 2025 outlook.IONSQ4 2024